Alzheimer's disease is known to be a chronic disease, with an estimated prevalence of about 10-30%, considering the population over 60 years of age. Most patients with this disorder (> 95%) present the sporadic form, being characterized by a late onset (80-90 years of age), and it is the consequence of the failure to clear the amyloid-β (Aβ) peptide from the interstices of the brain. Significant numbers of genetic risk factors for the sporadic disease have been researched. Some existing drugs for Alzheimer's disease provide symptomatic benefit for up to 12 months, but there are no approved disease- modifying therapies. In this line, a complementary strategy based on repositioning drugs which are approved for the treatment of other disorders could be interesting. It is noteworthy the fact that some clinical trials indicate that several classes of drugs own potent and beneficial effects on the Alzheimer's disease treatment. In this present work, we present the details and evaluation of these alternative treatments. It has highlighted several compounds with relevant evidence for this purpose, which deserves further investigation to clarify optimal treatment conditions in the clinical trials of patients with Alzheimer's disease.

Biomedical Research Center University Hospital Hradec Kralove Hradec Kralove Czech Republic

Center for Basic and Applied Research University Hradec Kralove Hradec Kralove Czech Republic

Department of Chemistry Federal University of Lavras Lavras MG 37200 000 Brazil

Department of Health Sciences Federal University of Espírito Santo São Mateus ES 29932 540 Brazil

References provided by Crossref.org

Future Therapeutic Perspectives into the Alzheimer's Disease Targeting the Oxidative Stress Hypothesis

Recent Developments in Metal-Based Drugs and Chelating Agents for Neurodegenerative Diseases Treatments